X4 Pharmaceuticals, Inc (XFOR) Financial Statements
X4 Pharmaceuticals, Inc (XFOR) reported trailing twelve-month revenue of $15.8M (down 51.6% year on year) and net income of -$90.1M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$83.7M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
XFORX4 Pharmaceuticals, IncFollow XFOR — free
—
Price chart with a free account
- Market cap
- 321.2M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 3 Nov, in 10 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2020 Dec 20 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|
| Revenue | 3.0 | 2.6 | 35.1 | 15.8 | |
| Gross profit | — | 1.8 | 29.4 | 12.9 | |
| Research & development | 41.9 | 81.6 | 72.7 | 66.4 | |
| Operating income | -59.9 | -36.4 | -86.9 | -87.9 | |
| Pre-tax income | -62.0 | -37.1 | -79.2 | -90.2 | |
| Income tax | 0.1 | 0.3 | 0.0 | -0.0 | |
| Net income | -62.1 | -37.5 | -79.2 | -90.1 | |
| Diluted EPS ($) | -3.09 | -5.59 | -1.87 | -0.72 | |
| Diluted shares (mn) | — | 6.7 | 42.3 | — |
USD millions · SEC XBRL
X4 Pharmaceuticals, Inc — questions
- What is X4 Pharmaceuticals, Inc's revenue?
- $15.8M over the twelve months to 2026-06-30, down 51.6% year on year, from its 10-Q and 10-K filings.
- What is X4 Pharmaceuticals, Inc's net income?
- -$90.1M over the twelve months to 2026-06-30.
- What is X4 Pharmaceuticals, Inc's free cash flow?
- -$83.7M over the twelve months to 2026-06-30.
- What are X4 Pharmaceuticals, Inc's diluted earnings per share?
- $-0.72 over the twelve months to 2026-06-30.
Every figure on this page comes from X4 Pharmaceuticals, Inc's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.